Unveiling the therapeutic potential of abaloparatide in treating periodontal dehiscence
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Sep-2025 01:11 ET (21-Sep-2025 05:11 GMT/UTC)
Alveolar bone defects can cause periodontal dehiscence, leading to exposure of dental roots, recession of gums, and increased tooth sensitivity. In a new study, researchers have evaluated the therapeutic potential of abaloparatide (ABL), a synthetic analog of human parathyroid hormone-related protein(PTHrP), in alleviating periodontal dehiscence. Utilizing rat models undergoing orthodontic tooth movement, they demonstrate that submucosal injection of ABL induces alveolar bone formation through a focal adhesion kinase(FAK)-driven mechanism.
A collaborative research team from Peking University has developed a novel method to enhance the tumor-targeting efficiency of γδ T cells through chemical engineering. By conjugating or gluing the cancer cell-targeting antibodies to γδ T cells via fast metabolic glycan labeling and click chemistry, the team achieved improved anti-tumor efficacy both in vitro and in vivo. This innovative approach holds significant promise for advancing adoptive cell therapy in cancer treatment.
A research team has developed a novel deep learning approach that significantly improves the accuracy of assessing plant leaf disease severity, a key step toward precision agriculture.
Neoadjuvant therapies, or treatments given before surgery, are changing how doctors treat locally advanced colon cancer. In a recent review, researchers from the United States examined how pre-surgical chemotherapy and immunotherapy can shrink tumors, reduce recurrence, and improve surgical outcomes. They discussed clinical trials like FOxTROT and NICHE and highlighted the importance of using mismatch repair (MMR) status to guide treatment decisions and improve patient outcomes through personalized care strategies.